Cytomegalovirus resistance testing: Pitfalls and problems for the clinician

Clinical Infectious Diseases

Volumn 50, Issue 5, 2010, Pages 733-736

  Lawrence Drew, W ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIVIRUS AGENT; CIDOFOVIR; FOSCARNET; GANCICLOVIR;

ANTIVIRAL ACTIVITY; ASSAY; CYTOMEGALOVIRUS INFECTION; GENOTYPE; HUMAN; PRIORITY JOURNAL; REVIEW; VIRUS RESISTANCE;

ANTIVIRAL AGENTS; CYTOMEGALOVIRUS; CYTOMEGALOVIRUS INFECTIONS; DNA, VIRAL; DRUG RESISTANCE, VIRAL; GENOTYPE; HUMANS; MICROBIAL SENSITIVITY TESTS;

EID: 76749100151     PISSN: 10584838     EISSN: None     Source Type: Journal    
DOI: 10.1086/650463     Document Type: Review

References (21)

1. Reddy AJ, Zaas AK, Hanson KE, Palmer SM. A single-center experience with ganciclovir-resistant cytomegalovirus in lung transplant recipients: treatment and outcome. J Heart Lung Transplant 2007;26:1286-1292.
2. Li F, Kenyon KW, Kirby KA, Fishbein DP, Boeckh M, Limaye AP. Incidence and clinical features of ganciclovir-resistant cytomegalovirus disease in heart transplant recipients. Clin Infect Dis 2007;45:439-447. (Pubitemid 47204459)
3. Limaye AP, Raghu G, Koelle DM, Ferrenberg J, Huang ML, Boeckh M. High incidence of ganciclovir-resistant cytomegalovirus infection among lung transplant recipients receiving preemptive therapy. J Infect Dis 2002; 185:20-27. (Pubitemid 34043012)
4. Eid AJ, Arthurs SK, Deziel PJ, Wilhelm MP, Razonable RR. Emergence of drug-resistant cytomegalovirus in the era of valganciclovir prophylaxis: therapeutic implications and outcomes. Clin Transplant 2008; 22:162-170.
5. Springer KL, Chou S, Li S, et al. How evolution of mutations conferring drug resistance affects viral dynamics and clinical outcomes of cytomegalovirus-infected hematopoietic cell transplant recipients. J Clin Microbiol 2005; 43:208-213. (Pubitemid 40096302)
6. Lurain NS, Bhorade SM, Pursell KJ, et al. Analysis and characterization of antiviral drug-resistant cytomegalovirus isolates from solid organ transplant recipients. J Infect Dis 2002;186:760-768
7. Marfori JE, Exner MM, Marousek GI, Chou S, Drew WL. Development of new cytomegalovirus UL97 and DNA polymerase mutations conferring drug resistance after valganciclovir therapy in allogeneic stem cell recipients. J Clin Virol 2007;38:120-125. (Pubitemid 46074451)
8. Avery RK, Bolwell BJ, Yen-Lieberman B, et al. Use of leflunomide in an allogeneic bone marrow transplant recipient with refractory cytomegalovirus infection. Bone Marrow Transplant 2004;34:1071. (Pubitemid 40028840)
9. Scott GM, Weinberg A, Rawlinson WD, Chou S. Multidrug resistance conferred by novel DNA polymerase mutations in human cytomeg-alovirus isolates. Antimicrob Agents Chemother 2007;51:89-94. (Pubitemid 46047692)
10. Rodriguez J, Casper K, Smallwood G, et al. Resistance to combined ganciclovir and foscarnet therapy in a liver transplant recipient with possible dual-strain cytomegalovirus coinfection. Liver Transpl 2007; 13:1396-1400 (Pubitemid 47629572)
11. Oshima K, Kanda Y, Kako S, et al. Case report: persistent cytomega-lovirus (CMV) infection after haploidentical hematopoietic stem cell transplantation using in vivo alemtuzumab: emergence of resistant CMV due to mutations in the UL97 and UL54 genes. J Med Virol 2008;80:1769-1775.
12. Drew WL, Miner R, Saleh E. Antiviral susceptibility testing of cytomegalovirus: criteria for detecting resistance to antivirals. Clin Diagn Viral 1993; 1:179-185
13. Chou S, Waldemer RH, Senters AE, et al. Cytomegalovirus UL 97 phosphotransferase mutations that affect susceptibility to ganciclovir. J Infect Dis 2002; 185:162-169. (Pubitemid 34056439)
14. Chou S, Lurain NS, Thompson KD, Miner RC, Drew WL. Viral DNA polymerase mutations associated with drug resistance in human cytomegalovirus. J Infect Dis 2003; 188:32-39. (Pubitemid 36829739)
15. Limaye AP. Ganciclovir-resistant cytomegalovirus in organ transplant recipients. Clin Infect Dis 2002; 35:866-872.
16. Smith IL, Cherrington JM, Jiles RE, Fuller MD, Freeman WR, Spector SA. High level resistance of cytomegalovirus to ganciclovir is associated with alterations in both the UL 97 and DNA polymerase genes. J Infect Dis 1997;176:69-77.
17. Eckle T, Lang P, Prix L, et al. Rapid development of ganciclovir- resistant cytomegalovirus infection in children after allogeneic stem cell transplantation in the early phase of immune cell recovery. Bone Marrow Transplant 2002;30:433-1139 (Pubitemid 35256415)
18. Drew WL, Miner RC, Busch DF, et al. Prevalence of resistance in patients receiving ganciclovir for serious CMV infection. J Infect Dis 1991;163:716-719.
19. Jabs DA, Enger C, Forman M, Dunn JP; the Cytomegalovirus Retinitis and Viral Resistance Study Group. Incidence of foscarnet resistance and cidofovir resistance in patients treated for cytomegalovirus retinitis. Antimicrob Agents Chemother 1998;42:2240-2244.
20. Nichols WG, Corey L, Gooley T, et al. Rising pp65 antigenemia during preemptive anticytomegalovirus therapy after allogenic hematopoietic stem cell transplantation: risk factors, correlation with DNA load, and outcomes. Blood 2001;97:867-874. (Pubitemid 32154267)
21. Drew WL. Is combination antiviral therapy for CMV superior to monotherapy? J Clin Virol 2006;35:485-1188